TG Therapeutics jumps after preliminary 2025 sales exceed forecast

TG Therapeutics

13/01/2026 23:42

** Shares of drugmaker TG Therapeutics TGTX.O up 7% at $29.88 in extended trading

** Preliminary full-year 2025 net sales of $616 million, compared to previous projection of $600 million

** Expects 2026 net sales in the range of $875 million to $900 million, compared to estimates of $895.6 million — data compiled by LSEG

** Co expects its new IV infusion schedule for multiple sclerosis drug Briumvi to boost revenue in the near term, if approved, says CEO Michael Weiss

** Stock fell marginally in 2025

(Reporting by Koyena Das in Bengaluru)

((koyena.das@thomsonreuters.com))